Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis on March 21, 2025 Apellis Approved C3 G Fabhalta Kidney Diseases Novartis pegcetacoplan Proteinuria United States Food and Drug Administration +